1239 |
Cilostazol as a Solution for Patients with Genetic Risk of Antiplatelet Therapy Resistance: Insights from the CILON-T Trial |
Kyung Woo Park |
May. 16. 11 |
1238 |
Optimal Treatment for Below-the-knee |
Young-Guk Ko |
May. 16. 11 |
1237 |
ACHILLES Study (DES for BTK) |
Andrej Schmidt |
May. 16. 11 |
1236 |
Rationale for the Use of Single Pill Combination and Asian Data of ARB/CCB SPC |
Seungwoo Park |
May. 16. 11 |
1235 |
Improving Effect of ARB to Asian Hypertension Patients |
Jeong Bae Park |
May. 16. 11 |
1234 |
A Single Center Clinical Experience Using Biolimus-Eluting Stent with Biodegradable Polymer |
Il Yi |
May. 16. 11 |
1233 |
BioMatrixTM: The Next Generation Biodegradable Polymer Technology - Korean Experience |
Kyung Woo Park |
May. 16. 11 |
1232 |
Evaluation of Effectiveness and Safety of BioMatrixTM - Biolimus A9TM stEnt in patients with AcUTe coronary sYndrome |
Young Joon Hong |
May. 16. 11 |
1231 |
Evidence Based Medicine: Does BioMatrixTM Bring Patient Benefit? - 3 Yr/Subgroup Follow Up from LEADERS Trial |
Eberhard Grube |
May. 16. 11 |
1230 |
The Real World Data & Experience of Zilver-PTX |
Bryan Ping-Yen Yan |
May. 16. 11 |